

*Subst B*

12. (Amended) The method of claim 11, comprising at least one substance having a lactone structure with a carbonyl moiety.

*Subst C*

13. (Amended) The method of claim 11, wherein at least one substance is coumarin, furanocoumarin, methoxsalen, imperatorin, psoralen,  $\alpha$ -naphthoflavone, isopimpinellin,  $\beta$ -naphthoflavone, bergapten, sphondin, coumatetralyl (racumin), (+)-cis-3,5-dimethyl-2-(3-pyridyl)-thiazolidim-4-one, naringenin and related flavones, diethyldithiocarbamate, N-nitrosodialkylamine, nitropyrene, menadione, imidazole antimycotics, miconazole, clotrimazole, pilocarpine, hexamethylphosphoramide, 4-methylnitrosamine-3-pyridyl-1-butanol, aflatoxin B, analogs thereof and derivatives thereof.

*AS Subst B*

16. (Amended) The method of any one of claims 11-15, wherein the condition is dependent or non-dependent tobacco use.

*Subst B*

21. (Amended) A pharmaceutical composition comprising an amount effective to regulate the metabolism of nicotine to cotinine wherein at least one substance selectively inhibits CYP2A6 and at least one substance inhibits CYP2B6.

*AC*

22. (Amended) The composition of claim 21, comprising at least one substance having a lactone structure with a carbonyl moiety.

*AC*

23. (Amended) The composition of claim 21, wherein at least one substance is coumarin, furanocoumarin, methoxsalen, imperatorin, psoralen,  $\alpha$ -naphthoflavone, isopimpinellin,  $\beta$ -naphthoflavone, bergapten, sphondin, coumatetralyl (racumin), (+)-cis-3,5-dimethyl-2-(3-pyridyl)-thiazolidim-4-one, naringenin and related flavones, diethyldithiocarbamate, N-nitrosodialkylamine, nitropyrene, menadione, imidazole antimycotics, miconazole, clotrimazole, pilocarpine, hexamethylphosphoramide, 4-methylnitrosamine-3-pyridyl-1-butanol, aflatoxin B, analogs thereof and derivatives thereof.

*AT10 Subj B*  
30. (Amended) The method of claim 25, wherein the condition is dependent or non-dependent on tobacco use.

*AT11 Subj B*  
38. (Amended) A method for treating a condition requiring regulation of nicotine metabolism to cotinine in an individual comprising administering to said individual: (a) an effective amount of a first substance which selectively inhibits CYP2A6; and (b) an effective amount of a second substance which is capable of inhibiting the metabolism of the first substance.

*Subj B*  
39. (New) The method of claim 11, wherein the substance is methoxsalen or derivatives thereof.

*Subj B*  
40. (New) The method of claim 16, wherein the substance is methoxsalen or derivatives thereof.

*AT2 Subj B*  
41. (New) The method of ~~claim 38~~, wherein at least one of said substances is methoxsalen or derivatives thereof.

*AT2*  
42. (New) A method for reducing nicotine intake comprising administering to the subject in need of reduced nicotine intake a substance which selectively inhibits CYP2A6.

*AT2*  
43. (New) The method of claim 42 comprising another substance capable of regulating inhibition of the first substance.

*AT2*  
44. (New) The method of claim 42, wherein said substance delays metabolism of nicotine to cotinine.